Zynyz (retifanlimab)
Merkel Cell Carcinoma
About Incyte
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
View full company profileAbout Incyte
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
View full company profileTherapeutic Areas
Other Merkel Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| FF-10850 | FUJIFILM Pharma | Phase 1 |